tbuckley/cabot-search huggingface dataset:
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
Authors: A. Matikas, T. Foukakis, V. Moebus, R. Greil, N. -O. Bengtsson, G.G. Steger, M. Untch, H. Johansson, M. Hellström, P. Malmström, M. Gnant, S. Loibl, J. Bergh
Journal: Annals of Oncology (2018)

BackgroundAdjuvant chemotherapy (ACT) for breast cancer improves relapse-free survival (BCRFS) and overall survival. Differences in terms of efficacy and toxicity could partly be explained by the significant interpatient variability in pharmacokinetics which cannot be captured by dosing according to body surface area. Consequently, tailored dosing was prospectively evaluated in the PANTHER trial.Patients and methodsPANTHER is a multicenter, open-label, randomized phase III trial which compared tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD) with standard interval 5-fluorouracil/E/C and D. The primary end point was BCRFS and the primary efficacy analysis has been previously published. In this secondary analysis, we aimed to retrospectively explore the concept of dose tailoring. Our two hypotheses were that BCRFS would not vary depending on the cumulative administered epirubicin dose; and that dose tailoring would lead to appropriate dosing and improved outcomes for obese patients, who are known to have worse prognosis and increased toxicity after DD ACT.ResultsPatients treated with tDD had similar BCRFS regardless of the cumulative epirubicin dose (P = 0.495), while obese patients in this group [body mass index (BMI) ≥30] had improved BCRFS compared with nonobese ones (BMI <30) [hazard ratio (HR) = 0.51, 95% confidence interval (CI) 0.30–0.89, P = 0.02]. Moreover, tDD was associated with improved BCRFS compared with standard treatment only in obese patients (HR = 0.49, 95% CI 0.26–0.90, P = 0.022) but not in nonobese ones (HR = 0.79, 95% CI 0.60–1.04, P = 0.089). The differences were not formally statistically significant (P for interaction 0.175). There were no differences in terms of toxicity across the epirubicin dose levels or the BMI groups.ConclusionsDose tailoring is a feasible strategy that can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies.ClinicalTrials.gov identifierNCT00798070.
P2.13-01 Brigatinib Use in England – Where Next?
Authors: F. Gomes, K. Yip, F. Blackhall, A. Greystoke, R. Califano, S. Ghosh, T. Newsom-Davis, H. Mills, S. Ahmed, A. Harle, Y. Summers
Journal: Journal of Thoracic Oncology (2018)
Elevated regulatory T cells at diagnosis of Coccidioides infection associates with chronicity in pediatric patients
Authors: Dan Davini, Fouzia Naeem, Aron Phong, Mufadhal Al-Kuhlani, Kristen M. Valentine, James McCarty, David M. Ojcius, David M. Gravano, Katrina K. Hoyer
Journal: Journal of Allergy and Clinical Immunology (2018)
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) in patients with pulmonary carcinoid tumours: Prevalence and prognosis of an under-recognised disease
Authors: A.R. Hayes, J. Banks, H. Shah, T.V. Luong, S. Navalkissoor, A. Grossman, D. Mandair, C. Toumpanakis, M. Caplin
Journal: Annals of Oncology (2018)
P3.01-33 EGFR Mutation in Patients with NSCLC and Its Relationship Between Survival and Clinicopathological Features: An Update Analysis
Authors: A. Ozturk, S. Celik, H. Kodaz, I. Yildiz, A. Ocak, I. Hacibekiroglu, I.V. Bayoglu, O. Ercelep, A.S. Ekinci, S. Menekse, O. Gumusay, B. Oven, M.N. Aldemir, C. Geredeli, M. Baykara, M. Uysal, A. Sevinc, A. Aksoy, A. Ulas, M. Inanc, O. Tanriverdi, N. Avci, N. Turan, M. Gumus
Journal: Journal of Thoracic Oncology (2018)
A novel electronic tool to implement palliative sedation (PS) in a department of oncologic medicine
Authors: A. Saviola, S. Cascinu, M. Salati, G. Longo, C. Fiorani, L. Ferrara, N. Malavasi, R. Postiglione, F. Cantile, L. Scarabelli, M. Rimini, F. Ferri
Journal: Annals of Oncology (2018)
Seeing the forest for the trees: fractal dimensions measure COPD airway remodeling
Authors: Eleanor M. Dunican
Journal: Journal of Clinical Investigation (2018)

Chronic obstructive pulmonary disease (COPD) is extremely heterogenous in its effects on airway remodeling. Parsing the complex and interrelated morphologic changes and understanding their contribution to disease severity has posed a significant challenge to the field. In the current issue of the JCI, Bodduluri et al. measured the complex effects of COPD on the airway tree using airway fractal dimension (AFD) on computerized tomography in a large cohort of smokers with and without COPD. They found that lower AFD was independently associated with disease severity and mortality in COPD. This work highlights AFD as a noninvasive approach to analyze complex changes in airway geometry.
Epidemiology of preterm birth in China in 2015 and 2016: a nationwide survey
Authors: Chang Chen, Jinwen Zhang, Hongwei Xia, Huixin Zhang, Ana Pilar Betran, Lin Zhang, Xiaolin Hua, Liping Feng, Dan Chen, Kang Sun, Chunming Guo, Hongbo Qi, Tao Duan, Jun Zhang
Journal: The Lancet (2018)
P2.04-30 PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Authors: K. Yin, Z. Xie, X. Yang, W. Guo, Y. Chen, W. Yan, J. Yang, Q. Zhou, W. Zhong, Y. Wu, X. Zhang
Journal: Journal of Thoracic Oncology (2018)
Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
Authors: J.A. Sorrentino, A. Lai, J.M. Weiss, K.H. Dragnev, T.K. Owonikoko, S. Adler, J.M. Antal, R.K. Malik, P.J. Roberts
Journal: Annals of Oncology (2018)
Abstract 18433: Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Blood Pressure as Mediators from Obesity to Ischemic Heart Disease
Authors: Anette Varbo, Marianne Benn, George Davey-Smith, Nicholas J Timpson, Anne Tybjærg-Hansen, Børge G Nordestgaard
Journal: Circulation (2014)

Introduction: Obesity leads to increased risk of ischemic heart disease(IHD), but the risk is probably mediated through intermediate variables and may not be caused by increased weight per se. Hypothesis: We tested the hypothesis that the increased risk of IHD due to obesity is mediated through lipoproteins, blood pressure, glucose, and/or C-reactive protein. Methods: 86,983 participants from Copenhagen were included in a Mendelian randomization design with mediation analyses. Associations were examined using conventional measurements of body mass index(BMI) and intermediate variables, and using genetic variants associated with these. During up to 22 years of follow-up 13,398 participants developed IHD. Results: The increased risk of IHD due to obesity was mediated through elevated levels of nonfasting remnant cholesterol and low-density lipoprotein(LDL) cholesterol, and through elevated blood pressure, and possibly also through elevated nonfasting glucose levels; however, reduced high-density lipoprotein...
P2.01-92 “All-In-One” Window: A New Way of Looking at Chest CT Studies in Thoracic Oncology
Authors: A. Snoeckx, P. Vuylsteke, B. Broeckx, K. Carpentier, R. Corthouts, E. Luyckx, S. Nicolay, A. Van Hoyweghen, M. Spinhoven, A. Janssens, J. Cant, J. Van Meerbeeck, P. Parizel
Journal: Journal of Thoracic Oncology (2018)
Quantifying circulating cell-free DNA as clinical biomarker
Authors: M. Romain, Z.A.A. Dache, A. Otandault, R. Tanos, B. Pastor, C. Sanchez, J. Azzi, G. Tousch, S. Azan, C. Mollevi, S. Thezenas, P. Blache, A.R. Thierry
Journal: Annals of Oncology (2018)
Prevalence, risk factors and management of opioid-induced constipation in cancer pain: A nationwide, cross-sectional study in Korea
Authors: S.Y. Lee, Y.S. Hong, K.T. Lee, S.H. Shin, M.Y. Choi, S.J. Sym, H.-S. Oh, S.N. Lee, E.-K. Song
Journal: Annals of Oncology (2018)
P2.04-15 Heterogeneity and Correlation Between Immune Markers in Lung Cancers: Analysis of Treatment-Naïve Lesions
Authors: K. Suda, J. Kim, I. Murakami, L. Rozeboom, C. Rivard, T. Mitsudomi, A. Tan, F. Hirsch
Journal: Journal of Thoracic Oncology (2018)
Cellular and Molecular Mechanisms of Prion Disease
Authors: Christina J. Sigurdson, Jason C. Bartz, Markus Glatzel
Journal: Annual Review of Pathology Mechanisms of Disease (2018)

Prion diseases are rapidly progressive, incurable neurodegenerative disorders caused by misfolded, aggregated proteins known as prions, which are uniquely infectious. Remarkably, these infectious proteins have been responsible for widespread disease epidemics, including kuru in humans, bovine spongiform encephalopathy in cattle, and chronic wasting disease in cervids, the latter of which has spread across North America and recently appeared in Norway and Finland. The hallmark histopathological features include widespread spongiform encephalopathy, neuronal loss, gliosis, and deposits of variably sized aggregated prion protein, ranging from small, soluble oligomers to long, thin, unbranched fibrils, depending on the disease. Here, we explore recent advances in prion disease research, from the function of the cellular prion protein to the dysfunction triggering neurotoxicity, as well as mechanisms underlying prion spread between cells. We also highlight key findings that have revealed new therapeutic targets and consider unanswered questions for future research.
P1.16-59 A Phase II Study of Adjuvant Chemotherapy with Tegafur-Uracil for Vessel Invasion Positive Stage IA Non-Small Cell Lung Cancer (LOGIK0602)
Authors: T. Tsuchiya, T. Nagayasu, R. Kamohara, M. Muraoka, S. Saeki, Y. Ichinose, M. Suzuki, K. Inada, S. Tokunaga, T. Hayashi, S. Urabe, T. Koga, S. Akamine, K. Sugio
Journal: Journal of Thoracic Oncology (2018)
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
Authors: Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, Daniel Wetterskog, Samanta Salvi, Giorgia Gurioli, Emanuela Scarpi, Elena Castro, Mercedes Marin-Aguilera, Cristian Lolli, Giuseppe Schepisi, Antonio Maugeri, Anna Wingate, Alberto Farolfi, Valentina Casadio, Ana Medina, Javier Puente, Mª José Méndez Vidal, Rafael Morales-Barrera, Jose C. Villa-Guzmán, Susana Hernando, Alejo Rodriguez-Vida, Aránzazu González-del-Alba, Begoña Mellado, Enrique Gonzalez-Billalabeitia, David Olmos, Gerhardt Attard, Ugo De Giorgi
Journal: European Urology (2018)

Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate whether docetaxel is active regardless of plasma AR and to perform an exploratory analysis to compare docetaxel with abiraterone/enzalutamide. This multi-institutional study was a pooled analysis of AR status, determined by droplet digital polymerase chain reaction, on pretreatment plasma samples. We evaluated associations between plasma AR and overall/progression-free survival (OS/PFS) and prostate-specific antigen (PSA) response rate in 163 docetaxel-treated patients. OS was significantly shorter in case of AR gain (hazard ratio [HR]=1.61, 95% confidence interval [CI]=1.08-2.39, p=0.018), but not PFS (HR=1.04, 95% CI 0.74-1.46, p=0.8) or PSA response (odds ratio=1.14, 95% CI=0.65-1.99, p=0.7). We investigated the interaction between plasma AR and treatment type after incorporating updated data from our prior study of 73 chemotherapy-naïve, abiraterone/enzalutamide-treated patients, with data from 115 first-line docetaxel patients. In an exploratory analysis of mCRPC patients receiving first-line therapies, a significant interaction was observed between plasma AR and docetaxel versus abiraterone/enzalutamide for OS (HR=0.16, 95% CI=0.06-0.46, p<0.001) and PFS (HR=0.31, 95% CI=0.12-0.80, p=0.02). Specifically, we reported a significant difference for OS favoring abiraterone/enzalutamide for AR-normal patients (HR=1.93, 95% CI=1.19-3.12, p=0.008) and a suggestion favoring docetaxel for AR-gained patients (HR=0.53, 95% CI=0.24-1.16, p=0.11). These data suggest that AR-normal patients should receive abiraterone/enzalutamide and AR-gained could benefit from docetaxel. This treatment selection merits prospective evaluation in a randomized trial. PATIENT SUMMARY: We investigated whether plasma androgen receptor (AR) predicted outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel, and we performed an exploratory analysis in patients treated with docetaxel or AR-directed drugs as first-line mCRPC therapy. We showed that plasma AR normal favored hormonal treatment, whilst plasma AR-gained patients may have had a longer response to docetaxel, suggesting that plasma AR status could be a useful treatment selection biomarker.
Anti-CTLA4 toxicity associates with genetic variation correlating with serum antibody diversity
Authors: D. Simpson, R. Ferguson, M. Gowen, K.M. Giles, J. Tchack, H. Zhou, U. Moran, Z. Dawood, A. Pavlick, S. Hu, M.A. Wilson, H. Zhong, M. Krogsgaard, J.S. Weber, I. Osman, T. Kirchhoff
Journal: Annals of Oncology (2018)
Abstract 17766: Active Intrathoracic Pressure Regulation Minimizes the Need for Vasopressors During Post Cardiac Arrest Care and Improves Cerebral Hemodynamics
Authors: Anja Metzger, Michael Lick, Paul Berger, Nicolas Segal, Aaron Robinson, Johanna Moore, Keith Lurie
Journal: Circulation (2016)

Background: Post cardiac arrest care is a critical aspect of survival after cardiac arrest. Active intrathoracic pressure regulation (a-IPR) therapy consists of the delivery of a positive pressure ventilation followed by a sub-atmospheric expiratory phase pressure of -10 cmH2O. A-IPR has previously been shown to improve cerebral hemodynamics in subjects with brain injury and low perfusion states. This study tested the hypothesis that a-IPR applied during a six hour post-ROSC period would enhance cerebral hemodynamics and require less vasopressor support. Methods: After 10 minutes of untreated ventricular fibrillation and six minutes of active compression decompression (ACD) CPR plus an impedance threshold device (ITD), 14 female pigs (39.1 ± 0.8 kg) were randomized into two post-ROSC treatment groups; one with continuous a-IPR therapy, the other without a-IPR therapy. A target mean arterial pressure (MAP) of 75 mmHg was achieved through controlled infusion of an epinephrine solution (0.002 mg/ml). MAP, va...
P1.09-37 Tumor Spread Through Air Spaces (STAS) in Stage I Lung Squamous Cell
Authors: H. Uruga, T. Fujii, S. Moriguchi, Y. Takahashi, K. Ogawa, R. Murase, S. Hanada, H. Takaya, A. Miyamoto, N. Morokawa, S. Fujimori, T. Kono, K. Kishi
Journal: Journal of Thoracic Oncology (2018)
P1.04-12 Mass Spectrometry-Based Serum Proteomic Signature as a Potential Biomarker for Survival in NSCLC Patients with Immunotherapy
Authors: Y. Chae, W.B. Kim, N. Simon, K. Rhee, J. Song, A. Cho, M. Oh, W. Iams, A. Davis, J. Anker, L.C. Park
Journal: Journal of Thoracic Oncology (2018)
Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with colorectal liver metastases
Authors: S. Stremitzer, A. Graf, B. Neudert, M. Herac, A. Beer, C. Schwarz, F. Wrba, K. Kaczirek, J. Stift
Journal: Annals of Oncology (2018)
P1.03-26 Analysis of DDR2 Gene Aberrations in Chinese Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis
Authors: J. Lai, W. Wang, C. Xu, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Everolimus after transarterial liver therapy of metastases from gastrointestinal neuroendocrine tumors: The FFCD 1104-EVACEL-GTE phase II study
Authors: T. Walter, C. Lepage, R. Coriat, E. Barbier, G. Cadiot, F.X. Caroli Bosc, T. Aparicio, K. Bouhier Leporrier, O. Hentic Dhome, A.-C. Dupont-Gossart, M. Duluc, C. Lepere, T. Lecomte, D. Smith, C. Petorin, I. Iwanicki Caron, M.P. Ducreux, C. Lombard Bohas, T. de Baere
Journal: Annals of Oncology (2018)
P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy
Authors: N. Rizvi, D. Gandara, B. Solomon, A. Kim, A. Brunelli, S. Sun, B. Gitlitz, K. Tajima, W. Lin, A. Sandler, S. Peters
Journal: Journal of Thoracic Oncology (2018)
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
Authors: A.D. Colevas, R. Bahleda, F. Braiteh, A. Balmanoukian, I. Brana, N.G. Chau, I. Sarkar, L. Molinero, W. Grossman, F. Kabbinavar, M. Fassò, C. O’Hear, J. Powderly
Journal: Annals of Oncology (2018)

BackgroundHead and neck cancer (HNC) has a poor prognosis at advanced stages. Given the immunosuppressive tumor microenvironment in HNC, inhibition of the programmed death-ligand 1/programmed death-1 (PD-L1/PD-1) signaling pathway represents a promising therapeutic approach. Atezolizumab (anti-PD-L1) is efficacious against many tumor types. Here we report the clinical safety and activity from the HNC cohort of the phase Ia PCD4989g clinical trial.Patients and methodsPatients with previously treated, advanced HNC received atezolizumab i.v. every 3 weeks for 16 cycles, up to 1 year or until loss of clinical benefit. Patients were monitored for safety and tolerability and evaluated for response at least every 6 weeks. Baseline PD-L1 expression level and human papillomavirus (HPV) status were evaluated.ResultsThirty-two patients were enrolled; 7 patients (22%) had a primary tumor in the oral cavity, 18 (56%) in the oropharynx, 1 (3%) in the hypopharynx, 2 (6%) in the larynx, and 4 (13%) in the nasopharynx. Seventeen patients (53%) had ≥2 prior lines of therapy. Twenty-one patients (66%) experienced a treatment-related adverse event (TRAE), with three experiencing grade 3 TRAEs and one experiencing a grade 4 TRAE (per CTCAE v4.0). No grade 5 TRAEs were reported. Objective responses by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) occurred in 22% of patients, with a median duration of response of 7.4 months (range 2.8–45.8 months). Median progression-free survival was 2.6 months (range 0.5–48.4 months), and median overall survival was 6.0 months (range 0.5–51.6+ months). Responses showed no association with HPV status or PD-L1 expression level.ConclusionsIn this heavily pre-treated advanced HNC cohort, atezolizumab had a tolerable safety profile and encouraging activity, with responses observed regardless of HPV status and PD-L1 expression level. These findings warrant further investigation of atezolizumab in HNC.ClinicalTrials.gov number: NCT01375842.
Effect of Early Sustained Prophylactic Hypothermia on Neurologic Outcomes Among Patients With Severe Traumatic Brain Injury
Authors: D. James Cooper, Alistair D. Nichol, Michael Bailey, Stephen Bernard, Peter A. Cameron, Sébastien Pili-Floury, Andrew Forbes, Dashiell Gantner, Alisa M. Higgins, Olivier Huet, Jessica Kasza, Lynne Murray, Lynette Newby, Jeffrey J. Presneill, Stephen Rashford, Jeffrey V. Rosenfeld, Michael Stephenson, Shirley Vallance, Dinesh Varma, Steven A. R. Webb, Tony Trapani, Colin McArthur
Journal: JAMA (2018)

After severe traumatic brain injury, induction of prophylactic hypothermia has been suggested to be neuroprotective and improve long-term neurologic outcomes.To determine the effectiveness of early prophylactic hypothermia compared with normothermic management of patients after severe traumatic brain injury.The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury-Randomized Clinical Trial (POLAR-RCT) was a multicenter randomized trial in 6 countries that recruited 511 patients both out-of-hospital and in emergency departments after severe traumatic brain injury. The first patient was enrolled on December 5, 2010, and the last on November 10, 2017. The final date of follow-up was May 15, 2018.There were 266 patients randomized to the prophylactic hypothermia group and 245 to normothermic management. Prophylactic hypothermia targeted the early induction of hypothermia (33°C-35°C) for at least 72 hours and up to 7 days if intracranial pressures were elevated, followed by gradual rewarming. Normothermia targeted 37°C, using surface-cooling wraps when required. Temperature was managed in both groups for 7 days. All other care was at the discretion of the treating physician.The primary outcome was favorable neurologic outcomes or independent living (Glasgow Outcome Scale-Extended score, 5-8 [scale range, 1-8]) obtained by blinded assessors 6 months after injury.Among 511 patients who were randomized, 500 provided ongoing consent (mean age, 34.5 years [SD, 13.4]; 402 men [80.2%]) and 466 completed the primary outcome evaluation. Hypothermia was initiated rapidly after injury (median, 1.8 hours [IQR, 1.0-2.7 hours]) and rewarming occurred slowly (median, 22.5 hours [IQR, 16-27 hours]). Favorable outcomes (Glasgow Outcome Scale-Extended score, 5-8) at 6 months occurred in 117 patients (48.8%) in the hypothermia group and 111 (49.1%) in the normothermia group (risk difference, 0.4% [95% CI, -9.4% to 8.7%]; relative risk with hypothermia, 0.99 [95% CI, 0.82-1.19]; P = .94). In the hypothermia and normothermia groups, the rates of pneumonia were 55.0% vs 51.3%, respectively, and rates of increased intracranial bleeding were 18.1% vs 15.4%, respectively.Among patients with severe traumatic brain injury, early prophylactic hypothermia compared with normothermia did not improve neurologic outcomes at 6 months. These findings do not support the use of early prophylactic hypothermia for patients with severe traumatic brain injury.clinicaltrials.gov Identifier: NCT00987688; Anzctr.org.au Identifier: ACTRN12609000764235.
Differential expression of immune checkpoints (PD-L1, HHLA2, B7x and B7H3) and their association with driver mutations in pulmonary sarcomatoid carcinoma (PSC)
Authors: H. Cheng, J. Sharma, C. Su, S. Li, X. Zang, R. Perez-Soler, B. Halmos, A. Borczuk
Journal: Annals of Oncology (2018)
P1.15-24 Small Cell Lung Cancer: Clinical Characteristics and Survival of a Spanish Cohort of 221 Patients
Authors: B. Núñez, R. Gómez, J. Sánchez, B. De La Puente, C. Alfaro, V. Calvo, L. Núñez, M. Blanco, I. Curto, M. Soriano, M. Méndez, A. Morito, F. Franco, M. Provencio
Journal: Journal of Thoracic Oncology (2018)
Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)
Authors: V. Prasad, R. Srirajaskanthan, C.M. Grana, S. Baldari, T. Shah, A. Lamarca, F. Courbon, K. Scheidhauer, E. Baudin, X.-M. Truong-Thanh, A. Houchard, L. Bodei
Journal: Annals of Oncology (2018)
P2.11-12 Metabolomic Analysis in Lung Cancer for Screening and Early Detection
Authors: N. Kajiwara, S. Maehara, H. Shimada, J. Maeda, M. Hagiwara, T. Okano, M. Kakihana, T. Ohira, M. Sugimoto, N. Ikeda
Journal: Journal of Thoracic Oncology (2018)
P1.15-20 Diagnosis and Treatment Delay Among Patients with Lung Cancer in Mexican Population
Authors: O. Macedo-Pérez, F. Talavera-Caro, I. Lyra-González, K. Campos-Peralta, N. Sobrevilla-Moreno, M.A. Alvarez-Avitia, E. Jiménez-Fuentes
Journal: Journal of Thoracic Oncology (2018)
P1.03-11 Analysis of T-Cell Repertoires in Benign and Malignant Solitary Pulmonary Nodules to Evaluate Tumor Immune Microenviroment
Authors: M. Li, S. Deng, S. Liu, B. Zhao, J. An, P. Deng, L. Cao, H. Yang, Q. Gu, H. Sun, Y. Wang, Y. Guan, X. Xia, X. Yi, C. Hu
Journal: Journal of Thoracic Oncology (2018)
Screening for Intimate Partner Violence, Elder Abuse, and Abuse of Vulnerable Adults
Authors: Jill Jin
Journal: JAMA (2018)

Cynthia Feltner, MD, MPH; Ina Wallace, PhD; Nancy Berkman, PhD; Christine E. Kistler, MD, MASc; Jennifer Cook Middleton, PhD; Collen Barclay, MPH; Laura Higginbotham, MD, MPH; Joshua T. Green, BA; Daniel E. Jonas, MD, MPH
P2.01-73 Automated Image Analysis Tool for Tumor Volume Growth Rate to Guide Precision Cancer Therapy: EGFR-Mutant NSCLC as a Paradigm
Authors: M. Nishino, S. Wakai, T. Hida, S. Dahlberg, M. Ozaki, H. Hatabu, H. Tachizaki, B. Johnson
Journal: Journal of Thoracic Oncology (2018)